Invention Grant
- Patent Title: Substituted fused heterocycles as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
-
Application No.: US15284213Application Date: 2016-10-03
-
Publication No.: US09758520B2Publication Date: 2017-09-12
- Inventor: Lothar Schwink , Christian Buning , Heiner Glombik , Matthias Gossel , Dieter Kadereit , Nis Halland , Matthias Lohmann , Christoph Pöverlein , Kurt Ritter
- Applicant: SANOFI
- Applicant Address: FR Paris
- Assignee: SANOFI
- Current Assignee: SANOFI
- Current Assignee Address: FR Paris
- Agency: Morrison & Foerster LLP
- Priority: EP14305494 20140404
- Main IPC: C07D401/02
- IPC: C07D401/02 ; C07D401/10 ; C07D401/14 ; A61K31/437 ; A61K31/4353 ; C07D471/04 ; C07D231/56 ; C07D249/18 ; A61K45/06 ; A61K31/4439 ; A61K31/155 ; A61K31/397 ; A61K31/40 ; A61K31/444 ; A61K31/702
Abstract:
The present invention relates to substituted fused heterocyclic compounds.The substituted fused heterocyclic compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of substituted fused heterocyclic compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
Public/Granted literature
Information query
